Voucher and NEW Patient Copay Assistance information is now available here

for Tardive Dyskinesia in Adults

Register for updates

MENU

About the clinical studies*

*Once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets contain the same active ingredient as twice-daily AUSTEDO tablets. Data on this page is based on twice-daily dosing.1

AUSTEDO (deutetrabenazine) tablets was studied in a diverse population with the goal of identifying the change in involuntary movements
—as measured by the Abnormal Involuntary Movement Scale (AIMS) total score—from the beginning to the end of the 12-week studies.1

A closer look at the data

98%

of people in one study were taking at least one mental health medication, including2,3:

Antidepressants:

  • 54%

    ANTIDEPRESSANTS
    AT BASELINE

Antipsychotics:

  • 62%

    ATYPICAL ANTIPSYCHOTICS

  • 14%

    TYPICAL OR COMBINATION ANTIPSYCHOTICS

  • 24%

    NO ANTIPSYCHOTICS AT BASELINE

Sex1

52 percent of women and 48 percent of men.

48%

48% MALE

52%

52% FEMALE

Underlying mental
health conditions3

50 percent have schizophrenia, 19 percent have depression, 17 percent have bipolar disorder, 10 percent have schizoaffective disorder, and 4 percent have other.

10%

10% SCHIZOAFFECTIVE
DISORDER

17%

17% BIPOLAR DISORDER

19%

19% DEPRESSION

4%

4% OTHER

50%

50% SCHIZOPHRENIA

Throughout both studies, people continued with their mental health medications while taking twice-
daily AUSTEDO to reduce tardive dyskinesia (TD) body movements.1,2

You Don't need to choose between maintaining
your mental health or treating TD1,2

Cherian Karunapuzha, neurologist, sitting in chair.

Watch professionals discuss treating
tardive dyskinesia with AUSTEDO

Patients can continue on their current psychiatric medication regimen along with the addition of AUSTEDO.

—Cherian Karunapuzha

Neurologist, Oklahoma City, OK

See healthcare providers share insights about TD

Stay in the know

Sign up for TD treatment tips, information about patient
support, and educational resources.

Sign up now

References:

1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

3. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. doi:10.1016/S2215-0366(17)30236-5

4. Abnormal Involuntary Movements Scale (AIMS) – overview. Medical Home Portal. Accessed February 28, 2023. https://www.medicalhomeportal.org/link/6544